Citigroup Begins Coverage on Dianthus Therapeutics (NASDAQ:DNTH)

Investment analysts at Citigroup started coverage on shares of Dianthus Therapeutics (NASDAQ:DNTH) in a research note issued to investors on Friday, Briefing.com reports. The brokerage set a “buy” rating and a $156.00 price target on the stock. Citigroup’s target price indicates a potential upside of 44.65% from the stock’s previous close.

DNTH has been the topic of a number of other reports. Guggenheim reiterated a “buy” rating on shares of Dianthus Therapeutics in a research report on Wednesday, June 10th. TD Cowen restated a “buy” rating on shares of Dianthus Therapeutics in a research report on Wednesday, June 10th. Wall Street Zen upgraded Dianthus Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, May 9th. Raymond James Financial reaffirmed a “strong-buy” rating and issued a $131.00 target price on shares of Dianthus Therapeutics in a research report on Wednesday, August 5th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Dianthus Therapeutics in a report on Friday, July 17th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Dianthus Therapeutics has an average rating of “Moderate Buy” and a consensus target price of $126.92.

Dianthus Therapeutics Stock Up 1.5%

Shares of NASDAQ:DNTH opened at $107.85 on Friday. The company has a market cap of $5.90 billion, a PE ratio of -25.99 and a beta of 1.24. Dianthus Therapeutics has a fifty-two week low of $23.70 and a fifty-two week high of $117.88. The firm has a 50-day simple moving average of $104.98 and a 200 day simple moving average of $88.94.

Dianthus Therapeutics (NASDAQ:DNTH) last issued its earnings results on Tuesday, August 4th. The company reported ($0.90) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.85) by ($0.05). Dianthus Therapeutics had a negative return on equity of 22.53% and a negative net margin of 10,096.95%.The business had revenue of $0.76 million during the quarter, compared to the consensus estimate of $0.30 million. As a group, research analysts forecast that Dianthus Therapeutics will post -3.83 EPS for the current fiscal year.

Insider Activity at Dianthus Therapeutics

In other news, CEO Marino Garcia sold 166,000 shares of the company’s stock in a transaction on Friday, August 7th. The stock was sold at an average price of $108.11, for a total value of $17,946,260.00. Following the completion of the sale, the chief executive officer owned 65,292 shares in the company, valued at $7,058,718.12. This represents a 71.77% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, EVP Simrat Randhawa sold 23,124 shares of the firm’s stock in a transaction dated Tuesday, September 1st. The shares were sold at an average price of $106.41, for a total value of $2,460,624.84. Following the transaction, the executive vice president directly owned 4,000 shares of the company’s stock, valued at $425,640. This represents a 85.25% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 283,678 shares of company stock worth $29,672,400 in the last quarter. Company insiders own 3.02% of the company’s stock.

Institutional Investors Weigh In On Dianthus Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the business. ABS Investment Management LLC bought a new position in shares of Dianthus Therapeutics during the 2nd quarter valued at about $194,960,000. PNC Financial Services Group Inc. grew its stake in shares of Dianthus Therapeutics by 0.4% in the 1st quarter. PNC Financial Services Group Inc. now owns 37,360 shares of the company’s stock worth $3,135,000 after purchasing an additional 139 shares during the last quarter. First Horizon Corp bought a new stake in shares of Dianthus Therapeutics in the 1st quarter worth approximately $32,000. Virtus Investment Advisers LLC raised its holdings in shares of Dianthus Therapeutics by 7.1% in the 4th quarter. Virtus Investment Advisers LLC now owns 6,315 shares of the company’s stock worth $260,000 after purchasing an additional 416 shares in the last quarter. Finally, EFG International AG acquired a new stake in Dianthus Therapeutics during the second quarter valued at approximately $49,000. 47.53% of the stock is owned by institutional investors and hedge funds.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.